CRISPR/dCas9 for Hepatic Fibrosis Therapy: Implications and Challenges

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2022 Aug 12

PMID 35960410

Authors

Nianan Luo

Wenjun Zhong

Jiangbin Li

Jianguo Lu

Rui Dong

Affiliations

Soon will be listed here.

Abstract

Hepatic fibrosis is a pathological reaction of tissue damage and repair caused by various pathogenic factors acting on liver. At present, there is no effective anti-fibrotic specific therapy. Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (dCas9) system is a new generation of gene editing technology. The CRISPR/dCas9 system provides a platform for studying site-specific transcriptional regulation, which has high efficiency in gene transcriptional activation for achieving robust. This system holds promise for hepatic fibrosis therapy via acting on liver fibrosis effector cells. However, there are some challenges associated with this novel technology, such as large structural variants at on-target, off-target sites, and targeted delivery efficiency. In this review, we present the potential implications and describe the challenges of CRISPR/dCas9 system that might be encountered in hepatic fibrosis therapy.

References

Friedman S, Pinzani M . Hepatic fibrosis 2022: Unmet needs and a blueprint for the future. Hepatology. 2021; 75(2):473-488. DOI: 10.1002/hep.32285. View

Flemming J, Dewit Y, Mah J, Saperia J, Groome P, Booth C . Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. Lancet Gastroenterol Hepatol. 2018; 4(3):217-226. DOI: 10.1016/S2468-1253(18)30339-X. View

Lu J, Xiang X, Cao Z, Wang W, Zhao G, Tang W . Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China. J Med Virol. 2017; 89(11):1973-1980. DOI: 10.1002/jmv.24894. View

Qing J, Ren Y, Zhang Y, Yan M, Zhang H, Wu D . Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis. J Hepatol. 2021; 76(2):394-406. DOI: 10.1016/j.jhep.2021.09.032. View

Foerster F, Gairing S, Muller L, Galle P . NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol. 2021; 76(2):446-457. DOI: 10.1016/j.jhep.2021.09.007. View

Lu Q, Zhou Y, Xu M, Liang X, Jing H, Wang X . Sequential delivery for hepatic fibrosis treatment based on carvedilol loaded star-like nanozyme. J Control Release. 2021; 341:247-260. DOI: 10.1016/j.jconrel.2021.11.033. View

Michalopoulos G, Bhushan B . Liver regeneration: biological and pathological mechanisms and implications. Nat Rev Gastroenterol Hepatol. 2020; 18(1):40-55. DOI: 10.1038/s41575-020-0342-4. View

Kisseleva T, Brenner D . Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2020; 18(3):151-166. DOI: 10.1038/s41575-020-00372-7. View

Banskota S, Raguram A, Suh S, Du S, Davis J, Choi E . Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell. 2022; 185(2):250-265.e16. PMC: 8809250. DOI: 10.1016/j.cell.2021.12.021. View

10.

Wood H . Mitochondrial dysfunction manifests in the early stages of Alzheimer disease. Nat Rev Neurol. 2020; 16(5):242. DOI: 10.1038/s41582-020-0353-3. View

11.

Giamas G, Gagliano T . Cancer gene therapy 2020: highlights from a challenging year. Cancer Gene Ther. 2021; 29(1):1-3. PMC: 8103066. DOI: 10.1038/s41417-021-00340-6. View

12.

Wang X, Li X, Ma Y, He J, Liu X, Yu G . Inhibition mechanisms of CRISPR-Cas9 by AcrIIA17 and AcrIIA18. Nucleic Acids Res. 2021; 50(1):512-521. PMC: 8754659. DOI: 10.1093/nar/gkab1197. View

13.

Park H, Kim D, Cho B, Byun J, Kim Y, Ahn Y . In vivo therapeutic genome editing via CRISPR/Cas9 magnetoplexes for myocardial infarction. Biomaterials. 2021; 281:121327. DOI: 10.1016/j.biomaterials.2021.121327. View

14.

Kim H, Park J, Lee S, Cho H, Park J, Kim J . Efficient CRISPR-Cas9-based knockdown of RUNX2 to induce chondrogenic differentiation of stem cells. Biomater Sci. 2021; 10(2):514-523. DOI: 10.1039/d1bm01716k. View

15.

Qi L, Larson M, Gilbert L, Doudna J, Weissman J, Arkin A . Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013; 152(5):1173-83. PMC: 3664290. DOI: 10.1016/j.cell.2013.02.022. View

16.

Konermann S, Brigham M, Trevino A, Joung J, Abudayyeh O, Barcena C . Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2014; 517(7536):583-8. PMC: 4420636. DOI: 10.1038/nature14136. View

17.

Maeder M, Linder S, Cascio V, Fu Y, Ho Q, Joung J . CRISPR RNA-guided activation of endogenous human genes. Nat Methods. 2013; 10(10):977-9. PMC: 3794058. DOI: 10.1038/nmeth.2598. View

18.

Chavez A, Scheiman J, Vora S, Pruitt B, Tuttle M, Iyer E . Highly efficient Cas9-mediated transcriptional programming. Nat Methods. 2015; 12(4):326-8. PMC: 4393883. DOI: 10.1038/nmeth.3312. View

19.

Jiang L, Ingelshed K, Shen Y, Boddul S, Iyer V, Kasza Z . CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies. Cancer Res. 2021; 82(1):36-45. PMC: 9397613. DOI: 10.1158/0008-5472.CAN-21-1692. View

20.

Fu R, He W, Dou J, Villarreal O, Bedford E, Wang H . Systematic decomposition of sequence determinants governing CRISPR/Cas9 specificity. Nat Commun. 2022; 13(1):474. PMC: 8789861. DOI: 10.1038/s41467-022-28028-x. View